LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

2018: European “1+ Million Genomes” Initiative launched

09/05/2021

Nominated by: Voisin Consulting Life Sciences

The European “1+ Million Genomes” Initiative builds from the achievements of the Human Genome Project and aims to have at least 1 million sequenced genomes available in the EU by 2022. The initiative aims to ensure secure, federated access to genomic data with ethical and legal implications of genomics fully considered. Research access to genomic data can enhance personalised medicine research, healthcare delivery and industry development of novel diagnostics and therapies, especially in rare diseases where patient options are still often limited.

The ‘1+ Million Genomes’ (1+MG) initiative brings together 22 EU countries, in addition to the UK and Norway, with the intention to promote public-private partnerships such as those seen in the Innovative Medicines Initiative, which brought together the world’s pharma, biotech, university and patient communities for ground-breaking pre-competitive research..  The initiative has the following supporting aims:

  • ensuring that appropriate technical infrastructure is available across the EU, allowing for secure, federated access to genomic data;
  • making sure that ethical and legal implications of genomics are clear and taken into account;
  • ensuring that the general public and policy makers in Member States and signatory countries are well informed about genomics, in order to ensure its uptake by healthcare systems and integration into personalised healthcare.

The project ‘Beyond 1 Million Genomes’ (B1MG) was established in 2020, with 28 participants from 25 countries to support initiative aims, primarily by addressing policies with citizen engagement and increasing genomic literacy.

In late 2020, the Commission created a special expert group (1+MG Group) with a view to formalising and facilitating the cooperation and coordination at the level of national representatives of the signatory countries. The group is co-chaired by the Commission and an EU country representative.

References:

  • European ” 1+Million Genomes Initiative
  • 1+Million Genomes Initiative Roadmap 2020-2022
  •  Project ”Beyond 1 Million Genomes’

 

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.